Publications by authors named "D V Starenki"

Background: In rheumatoid arthritis (RA), the activation of T and B cell clones specific for self-antigens leads to the chronic inflammation of the synovium. Here, we perform an in-depth quantitative analysis of the seven chains that comprise the adaptive immune receptor repertoire (AIRR) in RA.

Results: In comparison to controls, we show that RA patients have multiple and strong differences in the B cell receptor repertoire including reduced diversity as well as altered isotype, chain, and segment frequencies.

View Article and Find Full Text PDF

Despite significant advances in cancer diagnosis and treatment, osteosarcoma (OSA), an aggressive primary bone tumor, has eluded attempts at improving patient survival for many decades. The difficulty in managing OSA lies in its extreme genetic complexity, drug resistance, and heterogeneity, making it improbable that a single-target treatment would be beneficial for the majority of affected individuals. Precision medicine seeks to fill this gap by addressing the intra- and inter-tumoral heterogeneity to improve patient outcome and survival.

View Article and Find Full Text PDF

Tumors that metastasize in the peritoneal cavity typically end up in the omental adipose tissue, a particularly immune-suppressive environment that includes specialized adipose-resident regulatory T cells (Treg). Tregs rapidly accumulate in the omentum after tumor implantation and potently suppress antitumor immunity. However, it is unclear whether these Tregs are recruited from the circulation or derived from preexisting adipose-resident Tregs by clonal expansion.

View Article and Find Full Text PDF

Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor mainly caused by mutations in the proto-oncogene. We previously demonstrated that depletion of the mitochondrial molecular chaperone, mortalin, can effectively suppress human MTC cells in culture and in mouse xenografts, by disrupting mitochondrial bioenergetics and subsequently inducing apoptosis and RET downregulation. Similar effects were induced by MKT-077, a water-soluble rhodocyanine dye analog known to inhibit mortalin, but with notable toxicity in animals.

View Article and Find Full Text PDF
Article Synopsis
  • Obesity increases the risk of renal cancer and affects the effectiveness of immunotherapy, particularly anti-PD-1 treatments, making it crucial to understand these interactions as immunotherapy becomes more widely used.
  • In a study of renal cell carcinoma patients, obese individuals showed worse overall survival and progression-free survival rates compared to non-obese patients receiving anti-PD-1 therapy.
  • Animal models confirmed that obesity led to a lower frequency of effective CD8 T cells in tumors and reduced treatment response rates to immunotherapy, suggesting that obesity might hinder antitumor immunity.
View Article and Find Full Text PDF